In this special edition of PharmaVentures Insights, Dr Fintan Walton, CEO & Founder of PharmaVentures, leads a panel discussion to address whether a dual fundraising and partnering strategy is the best way forward for an emerging biotech.
Panelists include Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist Search and Evaluation at Novo Nordisk, Jeanne Bolger, Vice President, Venture Investments at Johnson & Johnson Innovation, Bart Dzikowski, Managing Director, Head of Transactions & Legal at Novartis Venture Fund, Tim…
Transine Therapeutics (‘Transine’), a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP® platform technology, announces that it successfully secured £9.1 million in seed funding. The financing was co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund (DDF), and will enable Transine to further develop its proprietary platform towards building a pipeline of novel mRNA-targeted therapeutics initially focused on the Central Nervous System and Ophthalmology applications.
Transine is based on the pioneering work of world-renowned geneticists…
Cambridge, UK: 1st June 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes providing members with opportunities to reduce operating costs without compromising their choice or independence. The One Nucleus Group Purchasing Scheme saves members over £3M per annum via negotiated Preferred Supplier Agreements. 001 Limited, a leader in Business Utility Services, Electricity, Gas, Telecommunications,…
Cambridge, UK: 27 May 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge, exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes promoting and leveraging the world class excellence within our network by facilitating the right connections. Charles River, a global leader in drug discovery and development has become the latest company to join the One Nucleus Partner Programme. The programme is tailor-made to meet the needs of the Partner and One…
AMSBIO reports upon a publication** that cites how its STEM-CELLBANKER® animal-free cryopreservation media has played a role in the development of a cell therapy for Parkinson’s Disease that will soon be going into clinical trials.Parkinson’s disease is one of the most common neurodegenerative diseases worldwide. Its main features include motor symptoms such as bradykinesia, rigidity, resting tremor, and postural instability, though non-motor symptoms are often also present. Currently the main therapy for Parkinson's disease consists of augmentation of dopamine levels…
Alderley Park, Cheshire Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and ADA analysis of Infex’s RESP-X program.
RESP-X is an anti-virulence therapy in-licensed from Japanese pharma company Shionogi. It is designed to help the body tackle Pseudomonas aeruginosa infections, a hard to treat drug-resistant pathogen recognised by the WHO as a critical threat to human health. A novel humanised monoclonal antibody, RESP-X does not kill bacteria directly but deactivates a mechanism that prevents the immune system from acting against the infection.
Dr Peter…
The Hotung Molecular Immunology group at St George’s, University of London has partnered with Leaf Expression Systems, a contract development and manufacturing organisation, specialising in plant-based expression and production of proteins, to explore the feasibility of producing anti-HIV monoclonal antibodies at large scale.
Led by Professor Julian Ma, the research team is trying to address the challenge of producing monoclonal antibodies to treat HIV-positive women late in pregnancy, to reduce the risk of passing the virus to their babies. They have recently developed several candidate…
Research Triangle Park, NC, USA and Cambridge, UK, 25 May 2021 -- Inivata, a leader in liquid biopsy, today announced a collaboration with F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, for the use of Inivata’s RaDaR technology.
Under the collaboration, Inivata’s RaDaR technology, a personalized assay that tracks a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity, will be applied to…
Funds will be used to advance pre-clinical and manufacturing development programmes and prepare for clinical studies.
Leeds, UK, 13 May 2021: LUNAC Therapeutics (LUNAC), a UK-based drug discovery company focused on the development of advanced life-saving anticoagulants, announces it has raised £4.75 million in an additional financing round.
The funding has come from Northern Powerhouse Investment Fund (NPIF) – Mercia Equity Finance, which is managed by Mercia and is part of the NPIF, the government’s Future Fund, and existing investors including Caribou Property Ltd and Epidarex Capital.
Dr.…
In a recent article in the New Scientist clinical trials supplement Dr Jorg Taubel, Scientific Lead at Richmond Research Institute, highlights the importance of reducing the risk to patients in phase I clinical trials.
As medicines become more personalised it will become necessary to conduct phase I trials directly with the target population. This must be approached with caution and improvements to phase I to trial design must be made before transferring the well-established healthy volunteer tool kit to patients who will often have complicated medical histories.
The drug action must be…